Ariad's Potential Blockbuster Set for EU Debut
Motley Fool
5 Can't-Miss Health-Care Events This Week
Motley Fool
3 Drug Launches You Need to Know in 2013
Motley Fool
7 Biotech Stocks Barclays Rates As Outperform
Seeking Alpha
Biotech 2012 Kickoff Party: Investor Preview
TheStreet.com
- Amag Pharmaceuticals
- Amarin
- Arena
- Ariad
- Biogen Idec
- Biomarin
- Celgene
- Clovis Oncology
- Dendreon
- Geron
- Gilead
- Human Genome Sciences
- Immunogen
- Incyte
- Indenix
- InterMune
- Keryx
- MannKind
- Medivation
- Merck KGaA
- Mesoblast
- ONYX Pharmaceuticals
- Regeneron
- Roche
- Seattle Genetics
- Spectrum Pharmaceuticals
- Vertex
- Vivus
- YM BioSciences
22 Hot Drugs Facing FDA Approval in 2012
TheStreet.com
- Amarin
- Amgen
- AMR101
- Amylin
- Ariad
- Avanafil
- Bio-T-Gel
- Biogen Idec
- BioSante
- Bristol-Myers Squibb
- Bydureon
- Carfilzomib
- Cell Therapeutics
- Chelsea Therapeutics
- Corcept Therapeutics
- Corlux
- Curis
- Dapagliflozin
- Discovery Labs
- Elan
- Eliquis
- Ironwood
- Kalydeco
- Levadex
- linaclotide
- MAP Pharmaceuticals
- Merck
- Northera
- ONYX Pharmaceuticals
- Pfizer
- pixantrone
- Protalix BioTherapeutics
- Qnexa
- ridaforolimus
- Roche
- Surfaxin
- Teva Pharmaceuticals
- Tysabri
- Uplypso
- Vertex
- vismodegib
- Vivus
- Xgeva
Submitted by moderatorj on Thu, 08/25/2011 - 21:47
Impressive Pipelines From Neoprobe and Ariad
Yahoo/MarketWire